Most cited papers from Almirall (Spain)

Almirall (Spain)

What are the most cited papers from Almirall (Spain)?

The most cited paper from Almirall (Spain) is "Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors" (María Pompeiano, JOSE M. PALACIOS, Guadalupe Mengod, 1994), with 883 citations. Next come "Phenotypic drug discovery: recent successes, lessons learned and new directions" (353) and "Prevalence and comorbidity of common mental disorders in primary care" (317).

Published TypeFieldAccessCitations

Showing 50 of 59 papers. Every paper with more than 86 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors María Pompeiano, JOSE M. PALACIOS, Guadalupe Mengod · Molecular Brain Research	Apr 1994	883
2	Phenotypic drug discovery: recent successes, lessons learned and new directions Fabien Vincent, Arsenio Nueda, Jonathan L. C. Lee et al. · Nature Reviews Drug Discovery ReviewOpen access	30 May 2022	353
3	Prevalence and comorbidity of common mental disorders in primary care Miquel Roca, Margalida Gili, M. García-García et al. · Journal of Affective Disorders	11 Apr 2009	317
4	Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts Axel Andrés, Martı́ Rosés, Clara Ràfols et al. · European Journal of Pharmaceutical Sciences Open access	9 May 2015	235
5	Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography S. Pérez-Torres, Xavier Miró, JOSE M. PALACIOS et al. · Journal of Chemical Neuroanatomy	Dec 2000	230
6	Early vs. Non-Early Intervention in Acute Migraine — ‘Act When Mild (AwM)’. A Double-Blind, Placebo-Controlled Trial of Almotriptan Peter James Goadsby, G Zanchin, G Géraud et al. · Cephalalgia	20 Feb 2008	223
7	Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2006 José Luis Llisterri Caro, G.C. Rodríguez Roca, Francisco Javier Alonso Moreno et al. · Medicina Clínica	May 2008	211
8	Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome Antonio Pascual, Marta Roqué i Figuls, Gerard Urrútia Cuchi et al. · Journal of Pain and Symptom Management ReviewOpen access	30 Mar 2004	185
9	Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Paul Jones, Dave Singh, Eric D Bateman et al. · European Respiratory Journal	22 Mar 2012	184
10	Resident Cell Chemokine Expression Serves as the Major Mechanism for Leukocyte Recruitment During Local Inflammation Eva García-Ramallo, Teresa Sá Marques, Neus Prats et al. · The Journal of Immunology Open access	Dec 2002	179
11	Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study Dave Singh, Paul Jones, Eric D Bateman et al. · BMC Pulmonary Medicine Open access	17 Nov 2014	177
12	Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study Marc Miravitlles, H. Worth, Juan José Soler‐Cataluña et al. · Respiratory Research Open access	20 Oct 2014	175
13	Transcription of a Broad Range of Self-Antigens in Human Thymus Suggests a Role for Central Mechanisms in Tolerance Toward Peripheral Antigens Mireia Sospedra, Xavier Ferrer-Francesch, Orlando Domı́nguez et al. · The Journal of Immunology	Dec 1998	173
14	Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial Bianca Maria Piraccini, Ulrike Blume‐Peytavi, Francesco Scarci et al. · Journal of the European Academy of Dermatology and Venereology Open access	11 Oct 2021	166
15	Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials Andrew Blauvelt, Jacob Pontoppidan Thyssen, Emma Guttman‐Yassky et al. · British Journal of Dermatology Open access	30 Mar 2023	163
16	Chemokines in autoimmune disease Núria Godessart, Steven L. Kunkel · Current Opinion in Immunology Review	Dec 2001	156
17	The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease Elena Gimeno‐Santos et al. · European Respiratory Journal Open access	28 May 2015	155
18	Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE) Ulrich Mrowietz, Jacek Cezary Szepietowski, Robert P. Loewe et al. · British Journal of Dermatology Open access	12 Aug 2016	151
19	Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial Jolana Marková, Ute Essner, Bülent Akmaz et al. · International Journal of Neuroscience	24 May 2018	149
20	Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study Anthony D D’Urzo, Stephen I. Rennard, Edward Kerwin et al. · Respiratory Research Open access	13 Oct 2014	149
21	Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks Kristian Reich, Richard Bruce Warren, Lars Iversen et al. · British Journal of Dermatology Open access	20 Jun 2019	148
22	Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD Henry Chrystyn, Mark A. Small, Gary W. Milligan et al. · Respiratory Medicine Open access	2 Oct 2013	147
23	Comorbidity between common mental disorders and chronic somatic diseases in primary care patients Margalida Gili, Àngels Comas, Margarita García-García et al. · General Hospital Psychiatry	2 Mar 2010	147
24	Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies James A. Heslop et al. · Stem Cells Translational Medicine Open access	26 Feb 2015	139
25	ANTIHISTAMINES AND DRIVING ABILITY: EVIDENCE FROM ON-THE-ROAD DRIVING STUDIES DURING NORMAL TRAFFIC David J. Roberts · Annals of Allergy Asthma & Immunology	Mar 2005	138
26	Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I) Edward Kerwin, Anthony D D’Urzo, Arthur F. Gelb et al. · COPD Journal of Chronic Obstructive Pulmonary Disease Open access	9 Feb 2012	133
27	Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile Amadeu Gavaldà, Montserrat Miralpeix, Israel Souza da Silva Ramos et al. · Journal of Pharmacology and Experimental Therapeutics	27 Aug 2009	131
28	A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis Jürgen Brück, Ralf Dringen, Adriana Amasuno et al. · Experimental Dermatology Open access	31 Mar 2018	128
29	Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate Sara Jane Bonvini, Mark A. Birrell, Megan S. Grace et al. · Journal of Allergy and Clinical Immunology Open access	11 Jan 2016	127
30	Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints Eamonn M.M. Quigley, Jan F. Tack, William D. Chey et al. · Alimentary Pharmacology & Therapeutics	Nov 2012	127
31	Epidemiology of risk factors and symptoms associated with menopause in Spanish women Jóse Antonio Martínez Pérez, Felipe Chavida García, Santiago Palacios et al. · Maturitas	18 Nov 2008	125
32	Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT) Eric D Bateman, Kenneth R. Chapman, Dave Singh et al. · Respiratory Research Open access	Aug 2015	117
33	Effect of propylene glycol on the skin penetration of drugs Víctor Carrer, Cristina Alonso, Mercè Pont et al. · Archives of Dermatological Research	30 Nov 2019	116
34	Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus Julio Cortijo, Josep Alberola Bou, Jörge Beleta et al. · British Journal of Pharmacology Open access	Feb 1993	113
35	Within‐Patient Early Versus Delayed Treatment of Migraine Attacks With Almotriptan: The Sooner the Better Julio Pascual, Xavier Cabarrocas · Headache The Journal of Head and Face Pain	2002	113
36	Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study Claus Franz Vogelmeier, Pier Luigi Paggiaro, Jordi Dorca et al. · European Respiratory Journal	4 Aug 2016	110
37	Impact of night-time symptoms in COPD: a real-world study in five European countries David Price, Small, Gary W. Milligan et al. · International Journal of COPD Open access	Nov 2013	110
38	Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study Jutta Beier, Anne‐Marie Kirsten, Robert Marek Mróz et al. · COPD Journal of Chronic Obstructive Pulmonary Disease Open access	2 Jul 2013	109
39	PDE4 inhibitors: a review of current developments (2005 – 2009) Lluı́s Pagès, Amadeu Gavaldà, Martin D. Lehner · Expert Opinion on Therapeutic Patents	16 Oct 2009	105
40	Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents Icilio Cavero, Roy Massingham, Francoise M. Lefevre-Borg · Life Sciences	Sep 1982	105
41	Characterization and solubilization of bitter-responsive receptors that couple to gustducin Ming Ding, Luis Ruíz-Ávila, Robert F. Margolskee · Proceedings of the National Academy of Sciences Open access	21 Jul 1998	104
42	Consistent Efficacy and Tolerability of Almotriptan in the Acute Treatment of Multiple Migraine Attacks: Results of a Large, Randomized, Double-Blind, Placebo-Controlled Study Julio Pascual, RM Falk, Frans Piessens et al. · Cephalalgia Open access	Jul 2000	103
43	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD François Maltais, Bartolomé R. Celli, Richard H. Casaburi et al. · Respiratory Medicine Open access	23 Dec 2010	102
44	Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)* Diamant Thaçi, Stefano Piaserico, Richard Bruce Warren et al. · British Journal of Dermatology Open access	8 Feb 2021	101
45	The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia E. Juncadella García, Marta Robert, Francesc Peris et al. · CNS Drugs	25 Jun 2009	99
46	Synthesis and Biological Evaluation of 3,4-Diaryloxazolones: A New Class of Orally Active Cyclooxygenase-2 Inhibitors Carles Puig, M. Crespo, Núria Godessart et al. · Journal of Medicinal Chemistry Open access	30 Dec 1999	98
47	Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD Rainard Fuhr, HELGO MAGNUSSEN, Kristina Sarem et al. · CHEST Journal	9 Sep 2011	97
48	Anticonvulsant-induced toxic epidermal necrolysis: Monitoring the immunologic response Laura Leyva, Marı́a José Torres, Sinforiano J. Posadas et al. · Journal of Allergy and Clinical Immunology Open access	2000	95
49	GSSG/GSH ratios in cryopreserved rat and human hepatocytes as a biomarker for drug induced oxidative stress Sònia Sentellas, Oriol Morales‐Ibanez, Míriam Zanuy et al. · Toxicology in Vitro	6 May 2014	95
50	Differential expression of SAP and EAT‐2‐binding leukocyte cell‐surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4) Xavier Romero, Daniel Benítez, S. March et al. · Tissue Antigens	6 May 2004	93

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.